Business

ValiRx engages US investor relations firm

ValiRx engages US investor relations firm.

articleValirx PlcMarch 17, 20163/company/valirx-plc/news/valirx-engages-us-investor-relations-firm
ValiRx engages US investor relations firm

About this update from Valirx Plc

[{"type":"text","content":"\n \nRNS Number : 3712S ValiRx PLC 17 March 2016  \n\n \n \n \nValiRx Plc\n(\"ValiRx\" or \"the Company\")\n \nVALIRX ENGAGES US INVESTOR RELATIONS FIRM\n \nLondon, UK, 17th March 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that subsequent to the Company's establishment of a US office (announced 05.11.15), the Group has engaged Burns McClellan, a leading US-based investor relations consultancy, on an on-going basis to help create broader recognition of the Company within the US life science investor community and to encourage and facilitate greater interaction with academic, clinical, and business leaders in ValiRx's areas of oncological development.\n \nBurns McClellan, founded over 25 years ago, is a healthcare investor relations specialist with considerable experience of supporting products and businesses in oncology with a wide range of US-based investors.  During the annual J.P. Morgan healthcare conference in San Francisco in mid-January 2016, Burns McClellan conducted an institutional investor introductory programme for ValiRx, on a project basis, which the Company found beneficial and has been keen to accelerate.\n \nSatu Vainikka, Chief Executive of ValiRx, commented: \"I am pleased our relationship with Burns McClellan is developing strongly, and I look forward to the Company benefitting from enhanced engagement with US investors and other key partners in the US biotech sector.\"\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nMark Treharne, Corporate Development Manager\n\n\nTel: +44 (0) 7736 564 686\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel: +44 (0) 20 7148 7900\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNorthland Capital Partners Limited (Broker)\n\n\nTel: +44 (0) 20 7382 1100\n\n\n\n\nPatrick Claridge / David Hignell (Corporate Finance)\nJohn Howes / Abigail Wayne (Broking)\n\n\n\n\n\n\n\n&nbsp...

More updates from Valirx Plc